Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ganglioside GM3 in preparation of medicine for treating atherosclerosis

A technology of atherosclerosis and gangliosides, applied in the field of preparation of drugs for the treatment of cardiovascular diseases, especially vascular atherosclerotic diseases, can solve the problem of affecting the integrity and permeability of the vascular endothelial layer, without atherosclerosis Drug research reports on sclerosis, unclear how GM3 affects the development of atherosclerosis, etc.

Pending Publication Date: 2019-11-29
NANCHANG UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Many studies have found that there is a large amount of ganglioside GM3 accumulation in the area of ​​arterial plaques, and the content of GM3 in atherosclerotic plaques is many times that of the normal inner wall of blood vessels. Many literatures have shown that GM3 affects the integrity and permeability of the vascular endothelium There are also reports in the literature that GM3 affects cell behaviors such as adhesion, proliferation and migration of tumor cells, fibroblasts, epidermal cells, etc., but it is still unclear how GM3 affects the formation of atherosclerosis and disease progression, and what role it plays. There is no research report on the development of GM3 as a drug for treating or delaying atherosclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ganglioside GM3 in preparation of medicine for treating atherosclerosis
  • Application of ganglioside GM3 in preparation of medicine for treating atherosclerosis
  • Application of ganglioside GM3 in preparation of medicine for treating atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0020] Example 1. Exogenous GM3 inhibits high-fat-fed ApoE - / - Atherosclerosis formation in C57BL / 6 mice.

[0021] ApoE with a high-fat diet - / - Male C57BL / 6 mice were used as model mice for atherosclerosis. The experiment was divided into 5 groups (6 mice in each group), respectively: Control group (normal ApoE without high-fat feeding - / - mice), Model group (ApoE fed with high-fat diet injected with normal saline - / - mice), High dose group (tail vein injection of high dose GM3 4mg / kg / 3d), Middle dose group (tail vein injection of medium dose GM3 1mg / kg / 3d), Low dose group (tail vein injection of low dose GM3 0.4mg / kg / 3d), continuous medication for 8 weeks while feeding with high fat.

[0022] (1) Blood lipid detection. After 8 weeks of medication, blood samples were taken from the mice (the mice were fasted for 12 hours before sampling); the serum samples were obtained by centrifugation at 3000rpm for 10 minutes; total cholesterol (TC), Triglyceride (TG), high-density...

example 2

[0031] Example 2. GM3 inhibits lipid precipitation (or foaming) of macrophages in vitro.

[0032] This part of the cell experiment is divided into the following five groups: (1) blank control group: mouse RAW264.7 macrophages without any stimulation or treatment; (2) positive control group: treated with 80um / ml oxidized low-density lipoprotein ( Ox-LDL) stimulated 6h of mouse RAW264.7 macrophages; (3) Experimental group 1: treated mouse RAW264.7 macrophages with 1μg / ml GM3 for 6h, then stimulated with 80μg / ml Ox-LDL Cells for 6h; (4) Experimental group 2: After treatment of mouse RAW264.7 macrophages with 10μg / ml GM3 for 6h, cells stimulated with 80um / ml Ox-LDL for 6h; (5) Experimental group 3: After treatment with 40μg / ml After treating mouse RAW264.7 macrophages with ml GM3 for 6 hours, the cells were stimulated with 80um / ml Ox-LDL for 6 hours; the above treatments or stimulations were all carried out in an incubator at 5% CO2 and 37°C, and then at room temperature Fix with...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of ganglioside GM3 in preparation of a medicine for treating cardiovascular and cerebrovascular diseases, which belongs to the technical field of cardiovascular disease drug effect research. In the application of the ganglioside GM3 in the medicine for treating cardiovascular and cerebrovascular diseases, the cardiovascular and cerebrovascular diseases are atherosclerosis. The invention also provides the medicine or a medicine composition for treating cardiovascular and cerebrovascular diseases, wherein an effective amount of ganglioside GM3 is used as aneffective component in the preparation of the medicine or the medicine composition for treating cardiovascular and cerebrovascular diseases. According to the invention, the drug effect of GM3 in the aspect of resisting atherosclerosis is clarified; a novel medicine choice is provided for treating cardiovascular diseases, especially atherosclerosis diseases in the cardiovascular diseases; in-vitroexperiments and animal experiment levels prove that the ganglioside GM3 has a definite effect on resisting atherosclerosis, so that the ganglioside GM3 has important research value and clinical application prospect when being used for treating cardiovascular diseases, particularly atherosclerosis diseases.

Description

technical field [0001] The invention belongs to the technical field of drug efficacy research on cardiovascular diseases, and specifically relates to the effect of ganglioside GM3 in delaying or treating cardiovascular diseases, especially vascular atherosclerotic diseases, and can be applied to the preparation and treatment of cardiovascular diseases, especially vascular arterial Drugs in atherosclerotic disease. Background technique [0002] Arteriosclerosis (Arteriosclerosis) has gradually increased in my country in recent years, and has become one of the main causes of death in the elderly, and it is still on the rise. Atherosclerosis (Atherosclerosis) is the most common and most important type of arteriosclerosis, which can lead to a variety of diseases or clinical symptoms, among which, the most well-known and most important is to cause myocardial infarction, coronary heart disease and stroke and other diseases Therefore, it can be said that atherosclerosis is the roo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7032A61P9/10
CPCA61K31/7032A61P9/10
Inventor 陈勇敖梅英黄洁周星王昆
Owner NANCHANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com